Fortekor Flavour 5 mg Tablets for Cats and Dogs

Dogs:
Rare
(1 to 10 animals / 10,000 animals
treated):
Diarrhoea, Vomiting,
Anorexia, Fatigue
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Elevated creatinine
,
Incoordination
In dogs with chronic kidney disease, the product may increase plasma creatinine
concentrations at the start of therapy. A moderate increase in plasma creatinine
concentrations following administration of ACE inhibitors is compatible with the reduction
AN: 00325/2025Page 3 of 7
in glomerular hypertension induced by these agents, and is therefore not necessarily a
reason to stop therapy in the absence of other signs.
In double-blind clinical trials in dogs with congestive heart failure, the veterinary medicinal
product was well tolerated with an incidence of adverse reactions lower than observed in
placebo-treated dogs.
Cats:
Rare
(1 to 10 animals / 10,000 animals
treated):
Diarrhoea, Emesis,
Anorexia, Dehydration, Lethargy
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Elevated creatinine
,
Increased appetite, Weight gain
In cats with chronic kidney disease, the product may increase plasma creatinine
concentrations at the start of therapy. A moderate increase in plasma creatinine
concentrations following administration of ACE inhibitors is compatible with the reduction
in glomerular hypertension induced by these agents, and is therefore not necessarily a
reason to stop therapy in the absence of other signs.

Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See package leaflet for respective
contact details.